6242 Stock Overview
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks.
Li Kang Biomedical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||NT$45.55|
|52 Week High||NT$78.57|
|52 Week Low||NT$35.71|
|1 Month Change||-5.99%|
|3 Month Change||-2.99%|
|1 Year Change||23.91%|
|3 Year Change||19.42%|
|5 Year Change||10.97%|
|Change since IPO||-86.77%|
Recent News & Updates
|6242||TW Personal Products||TW Market|
Return vs Industry: 6242 exceeded the TW Personal Products industry which returned -8.5% over the past year.
Return vs Market: 6242 exceeded the TW Market which returned -19.7% over the past year.
|6242 Average Weekly Movement||6.2%|
|Personal Products Industry Average Movement||5.8%|
|Market Average Movement||5.1%|
|10% most volatile stocks in TW Market||8.3%|
|10% least volatile stocks in TW Market||2.5%|
Stable Share Price: 6242 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: 6242's weekly volatility (6%) has been stable over the past year.
About the Company
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drinks. It also engages in management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd.
Li Kang Biomedical Fundamentals Summary
|6242 fundamental statistics|
Is 6242 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|6242 income statement (TTM)|
|Cost of Revenue||NT$209.43m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||3.15|
|Net Profit Margin||14.72%|
How did 6242 perform over the long term?See historical performance and comparison
3.1%Current Dividend Yield
Is 6242 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 4/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 6242?
Other financial metrics that can be useful for relative valuation.
|What is 6242's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 6242's PE Ratio compare to its peers?
|6242 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
4732 NatureWise Biotech & Medicals
6703 Shiny Brands Group
8480 Taisun Int'l (Holding)
6242 Li Kang Biomedical
Price-To-Earnings vs Peers: 6242 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the peer average (17.5x).
Price to Earnings Ratio vs Industry
How does 6242's PE Ratio compare vs other companies in the Asian Personal Products Industry?
Price-To-Earnings vs Industry: 6242 is good value based on its Price-To-Earnings Ratio (14.5x) compared to the Asian Personal Products industry average (25.5x)
Price to Earnings Ratio vs Fair Ratio
What is 6242's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||14.5x|
|Fair PE Ratio||n/a|
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 6242's Price-To-Earnings Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of 6242 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 6242 (NT$45.55) is trading below our estimate of fair value (NT$59.86)
Significantly Below Fair Value: 6242 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
How is Li Kang Biomedical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Household industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Li Kang Biomedical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Examine whether Li Kang Biomedical is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
How has Li Kang Biomedical performed over the past 5 years?
Past Performance Score1/6
Past Performance Score 1/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6242 has high quality earnings.
Growing Profit Margin: 6242's current net profit margins (14.7%) are lower than last year (15.4%).
Past Earnings Growth Analysis
Earnings Trend: 6242's earnings have declined by 15.3% per year over the past 5 years.
Accelerating Growth: 6242's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 6242 had negative earnings growth (-7.4%) over the past year, making it difficult to compare to the Personal Products industry average (-11.6%).
Return on Equity
High ROE: 6242's Return on Equity (14.6%) is considered low.
Discover strong past performing companies
How is Li Kang Biomedical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 6242's short term assets (NT$296.6M) exceed its short term liabilities (NT$156.8M).
Long Term Liabilities: 6242's short term assets (NT$296.6M) exceed its long term liabilities (NT$31.7M).
Debt to Equity History and Analysis
Debt Level: 6242 has more cash than its total debt.
Reducing Debt: 6242's debt to equity ratio has reduced from 21.3% to 5.7% over the past 5 years.
Debt Coverage: 6242's debt is well covered by operating cash flow (291.6%).
Interest Coverage: 6242 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Li Kang Biomedical current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
|Li Kang Biomedical Dividend Yield vs Market|
|Company (Li Kang Biomedical)||3.1%|
|Market Bottom 25% (TW)||2.6%|
|Market Top 25% (TW)||7.1%|
|Industry Average (Personal Products)||3.9%|
|Analyst forecast in 3 Years (Li Kang Biomedical)||n/a|
Notable Dividend: 6242's dividend (3.14%) is higher than the bottom 25% of dividend payers in the TW market (2.63%).
High Dividend: 6242's dividend (3.14%) is low compared to the top 25% of dividend payers in the TW market (7.14%).
Stability and Growth of Payments
Stable Dividend: 6242 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 6242's dividend payments have increased, but the company has only paid a dividend for 7 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (45.4%), 6242's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (41.1%), 6242's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Li Kang Biomedical has no CEO, or we have no data on them.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
|Owner Type||Number of Shares||Ownership Percentage|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Li Kang Biomedical Co., Ltd.'s employee growth, exchange listings and data sources
- Name: Li Kang Biomedical Co., Ltd.
- Ticker: 6242
- Exchange: TPEX
- Founded: 1982
- Industry: Personal Products
- Sector: Household
- Implied Market Cap: NT$1.062b
- Shares outstanding: 23.31m
- Website: https://www.likangbio.com
Number of Employees
- Li Kang Biomedical Co., Ltd.
- No. 29, Huangong Road
- Yongkang District
- Tainan City
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|6242||TPEX (Taipei Exchange)||Yes||Common Stock||TW||TWD||Apr 2003|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/29 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.